对于复发性质母细胞瘤的MTX110的Biodexa药业公司的MAGIC-1研究显示了更好的生存率. Biodexa Pharmaceuticals' MAGIC-1 study of MTX110 for recurrent glioblastoma shows improved survival rates.
Biodexa Pharmaceuticals 宣布了其 MTX110 的 MAGIC-1 研究的积极结果，MTX110 是一种治疗复发性胶质母细胞瘤 （rGBM），一种严重的脑癌。 Biodexa Pharmaceuticals announced positive results from its MAGIC-1 study of MTX110, a treatment for recurrent glioblastoma (rGBM), a severe brain cancer. MTX110结合了药物的全色固态与直接针对肿瘤、有效绕过血脑屏障的对流强化运载系统。 MTX110 combines the drug panobinostat with a convection-enhanced delivery system that directly targets tumors, effectively bypassing the blood-brain barrier. 这项研究显示,无进展和整体生存率有所改善,这表明对RGBM和扩散中线质瘤等侵袭性脑癌的治疗标准可能有所改变. The study shows improved progression-free and overall survival rates, suggesting a potential shift in treatment standards for rGBM and aggressive brain cancers like diffuse midline glioma.